Antibiotic Incentives Moving Forward: “Cures” Act Pathway May Apply More Broadly
This article was originally published in RPM Report
Anti-infective drug development companies appear set to receive another round of legislative incentives as the “Cures” process moves forward. The only question is when and how much they will receive. One provision—creating a new limited use pathway—could be important for all classes of drug development.
Register for our free email digests: